Strong Start to Sales of Karolinska Development's New Share Issue

Stockholm, November 20 (ots/PRNewswire) - Karolinska Development AB,
have launched a new share issue up to a value of 147 million Swedish
Kronor, (19 million USD) which has opened with a strong start to
sales.

To view the Multimedia News Release, please click:

http://www.prnewswire.com/mnr/karolinskadevelopment/36025/

"We are very excited to have such strong financial backing from
this outstanding group of investors, whose participation in this
round further validates our business strategy and the value we bring
to our life science innovations," said Conny Bogentoft, Chief
Executive Officer of Karolinska Development (KD). The portfolio of
38 companies includes three which have non-pharmaceutical products
that are in the process of being launched, five have pharmaceutical
compounds undergoing Phase II clinical studies and four have
compounds in Phase I clinical studies. KD has a very effective
business model which has enabled this to be done in less than 5
years and for less than 600 Million SEK, (77 Million USD) the
resulting portfolio comprises a product pipeline comparable with
that of a major pharmaceutical company. "This is an incredible
achievement," says Bogentoft "and is in stark contrast to the
amounts traditionally spent by pharmaceutical companies to achieve
similar results." KD not only has an extremely cost effective
business model, the speed at which KD has progressed its portfolio is
also impressive. Dilafor for example has taken their first in class
compound for protracted labor during childbirth from concept to Phase
II in only 5 years, further validating the KD business model. "We
don't just invest in our portfolio companies. We partner with them,
our team brings decades of operating experience, market knowledge,
and a global network to every company in the portfolio." Says
Bogentoft.

One of the company's goals is to prove that long-term investment
in good academic science pays off in a number of ways. "Creating
jobs, creating new products that will benefit society and making
money," he says. "We haven't proved the latter yet, but that is what
we want to do over the next three years." KD has one of Europe's
largest life science portfolios and the increasing degree of maturity
within the portfolio companies is reflected in the increase in value
of Karolinska Development, however this also brings increased demands
on the financing needed. The proceeds of this financing will be used
to provide the capital necessary to continue this development of the
portfolio.

This share issue is being handled by EFG Investment Bank who has
worked with Karolinska Development on three previous share offers, a
prospectus of this offering has been filed with the Swedish Finance
Inspection (FI). Copies of the prospectus for this offering may be
obtained from EFG Investment Bank:

Attn: Prospectus Department, Box 559 64
102 16 Stockholm
Telephone: +46(0)8-459-64-63
email: info@efgib.com

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Karolinska Development

Karolinska Development is a Swedish investment company using a
unique, highly cost effective model to commercialize internationally
renowned life science innovations. Professionals in business
development and management, supported by a network of experienced
technical specialists, ensure fast and efficient development. This
enables Karolinska Development to rapidly build value in high risk
opportunities, through long term lead investor position from seed
stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska
Institute Science Park, Sweden www.karolinskadevelopment.com

About EFG Investment Bank

EFG Investment Bank, residence Stockholm, is an asset management
bank, specialized in index-linked asset allocation in liquid markets
and uncorrelated investments. EFG Investment Bank is a wholly owned
subsidiary to EFG International, with head office in Zurich and
offices in more than 30 countries. EFG International (EFGN) is listed
on SWX Swiss Exchange and has approximately 1 500 employees. The Bank
is a part of EFG Group which is, measured in Tier-1 Capital, the
third largest banking group in Switzerland.

For further information contact:

Conny Bogentoft, CEO, telephone: +46(0)70-668-6143, e-post:
conny.bogentoft@kab.ki.se

ots Originaltext: Karolinska Development AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information contact: Conny Bogentoft, CEO, telephone:
+46(0)70-668-6143, e-post: conny.bogentoft@kab.ki.se